TYRA:NASDAQTyra Biosciences, Inc. Analysis

Tyra Biosciences trades at $33.17, just above its 20‑day SMA of 34.32 and well below the 200‑day SMA of 24.83, indicating a neutral technical stance. The RSI sits at 43, MACD is bearish, and volatility is elevated at 47% over the past 30 days, suggesting short‑term price swings. Despite a negative earnings profile (trailing EPS -2.18, forward PE -11.69) the company holds $383 M in cash against modest debt, and analysts have a strong‑buy consensus with a median 12‑month price target of $53, implying >50% upside. The fear‑and‑greed index reads “Extreme Greed,” reflecting market optimism, but the biotech sector’s inherent regulatory and clinical‑trial risks remain high.
Given the solid cash runway, promising FGFR‑focused pipeline, and substantial upside potential relative to current valuation, TYRA appears undervalued for growth‑oriented investors, though the near‑term technical indicators and high volatility advise caution.